AMI-1 free acid

Research use only, not for human use.

AMI-1 free acid is a potent, cell-permeable, and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with inhibitory concentration 50 (IC50) values of 8.8 μM for human PRMT1 and 3.0 μM for yeast-Hmt1p.

AMI-1 free acid is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 free acid exerts PRMTs inhibitory effects by blocking peptide-substrate binding.

AMI-1 free acid can inhibit the in vitro methylation reactions performed by all five recombinantly active PRMTs (PRMT1, -3, -4, and -6 and Hmt1p).AMI-1 free acid not only inhibits type I PRMTs (PRMT1, 3, 4 and 6) but also type II PRMT5. AMI-1 free acid specifically inhibits arginine, but not lysine, methyltransferase activity in vitro and does not compete for the AdoMet binding site. AMI-1 free acid inhibits methylation of GFP-Npl3 and cellular proteins.AMI-1 free acid (0.6-2.4 mM; 48-96 hours) inhibits the cell viability of sarcoma in S180 and U2OS cells in a time-dependent and dose-dependent manner in vitro.AMI-1 free acid (1.2-2.4 mM; 48-72 hours) reduces S180 cell viability through the induction of cell apoptosis.Cell Viability Assay Cell Line:S180 cells, U2OS cells Concentration:0.6 mM, 1.2 mM, 2.4 mM Incubation Time:48 hours, 72 hours, 96 hours Result:Inhibited the cell viability.Apoptosis Analysis Cell Line:S180 cellsConcentration:1.2 mM, 2.4 mM Incubation Time:48 hours, 72 hours Result:Increased the percentages of cells undergoing apoptosis.

AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) inhibits S180 viability in vivo.AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) downregulates PRMT5 but does not regulate the expression of PRMT7 in a tumor xenograft model.AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) decreases the levels of H4R3me2s and H3R8me2s in a tumor xenograft model.Animal Model:6-7 weeks old male Kunming mice (18-22 g), with S180 cells xenograft Dosage:0.5 mg Administration: Intratumorally, daily, for 7 days Result:Decreased tumor weight.

——

Others

Other Targets

Histone Methyltransferase

——

——

134-47-4

504.49

C21H16N2O9S2

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (165.18 mM; Ultrasonic )

O=C(NC=1C=CC2=C(O)C=C(C=C2C1)S(=O)(=O)O)NC=3C=CC4=C(O)C=C(C=C4C3)S(=O)(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years